Connecticut Attorney General George Jepsen said Tuesday the state will get about $1.5 million from Ranbaxy, the India-based generic drug maker, who settled allegations this week that it was selling generics that were less than full strength or less than pure.
Ranbaxy agreed to settle the charges after a whistleblower made allegations about its drugs in court. The feds and states got involved because, ultimately because Medicaid, like private insurance policies, pushes patients to use cheaper generics when available. In all, the Indian pharmaceutical made 26 generic type of drugs between 2003 and 2010.
Ranbaxy agreed to pay fines and restitution to Medicaid programs, while not admitting it did anything wrong.